Leerink Lowers Karyopharm Price Target Amid Mixed Trial Data Results

Leerink has reduced its price target for Karyopharm Therapeutics to $10 from $15 following the release of mixed data from clinical trials. This adjustment reflects the market's reaction to the trial outcomes, which have raised concerns about the drug's efficacy. Karyopharm's stock was last traded at $8.50, indicating a 1.5% decline from the previous trading session. The lowered price target could impact investor sentiment and trading behavior around Karyopharm shares.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.